Class Action Notice for Mereo BioPharma Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 12 2026
0mins
Should l Buy MREO?
Source: Globenewswire
- Class Action Initiation: The Portnoy Law Firm advises Mereo BioPharma Group plc investors of a class action for those who purchased securities between June 5, 2023, and December 26, 2025, with a deadline for lead plaintiff motions set for April 6, 2026.
- False Statements Revealed: The complaint alleges that Mereo misled investors by providing overly positive statements while concealing adverse facts regarding the Phase 3 ORBIT and COSMIC programs, which significantly impacted investor decisions.
- Poor Study Results: On December 29, 2025, Mereo announced that neither the ORBIT nor COSMIC studies achieved statistical significance, failing to meet their primary endpoint of reducing clinical fracture rates, despite improvements in bone mineral density.
- Stock Price Collapse: Following the negative announcement, Mereo's ADS price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, representing a decline of over 87.7%, severely affecting investor asset values.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MREO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MREO
Wall Street analysts forecast MREO stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.399
Low
0.50
Averages
2.08
High
5.00
Current: 0.399
Low
0.50
Averages
2.08
High
5.00
About MREO
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investors Alert: Deadline for Class Action Lawsuits Approaches
- Lawsuit Overview: Holzer & Holzer, LLC reminds investors of the class action lawsuit against BlackRock TCP Capital Corp., alleging that from November 6, 2024, to January 23, 2026, the company failed to appropriately value investments, resulting in significant investor losses.
- Mereo BioPharma Lawsuit: The class action against Mereo BioPharma Group plc claims that between June 5, 2023, and December 26, 2025, the company did not disclose material facts regarding setrusumab's statistical significance in the ORBIT and COSMIC studies, impacting investor confidence.
- Pomdoctor Lawsuit: The class action against Pomdoctor Limited alleges involvement in a fraudulent stock promotion scheme through social media misinformation from October 9, 2025, to December 11, 2025, leading to investor losses, with a deadline of April 6, 2026, to apply as lead plaintiff.
- Ultragenyx Lawsuit: The class action against Ultragenyx Pharmaceutical Inc. alleges failure to disclose expected results for its Phase III studies from August 3, 2023, to December 26, 2025, urging investors to act before the April 6, 2026, deadline.
See More
Class Action Filed Against Mereo BioPharma Group plc for Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Mereo BioPharma Group plc, alleging violations of federal securities laws on behalf of all investors who purchased Mereo securities between June 5, 2023, and December 26, 2025.
- False Statements Allegations: The complaint claims that throughout the class period, the defendants made overly positive statements while concealing significant adverse facts regarding the Phase 3 ORBIT and COSMIC programs, misleading investors about the company's true condition.
- Investor Actions: Affected investors are encouraged to apply to be lead plaintiffs by April 6, 2026, to share in any potential recovery, with the assurance that participation does not require serving as lead plaintiff.
- Law Firm's Strength: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors, emphasizing its commitment to restoring investor capital and ensuring corporate accountability.
See More
Mereo BioPharma Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Mereo BioPharma Group plc, encouraging those who purchased shares between June 5, 2023, and December 26, 2025, to contact the firm regarding potential lead plaintiff status for recovery.
- False Statements Allegations: The complaint alleges that Mereo provided overly positive statements about the Phase 3 ORBIT and COSMIC programs while concealing significant adverse facts, misleading investors about the trials' failure to meet primary endpoints.
- Stock Price Collapse: Following a press release on December 29, 2025, stating that neither study achieved statistical significance, Mereo's ADS price plummeted from $2.31 on December 26, 2025, to $0.29, representing a decline of over 87.7%.
- Claim Deadline: Shareholders must register by April 6, 2026, to participate in the class action lawsuit, and upon registration, they will receive updates on the case's progress to ensure their rights are protected.
See More
Class Action Notice for Mereo BioPharma Investors
- Class Action Deadline: Investors in Mereo BioPharma Group plc must note that the deadline to apply as lead plaintiff is April 6, 2026, covering the period from June 5, 2023, to December 26, 2025, and failure to apply may result in loss of claims.
- Lawsuit Background: The lawsuit alleges that Mereo's positive statements regarding setrusumab in its Phase 3 Orbit and COSMIC studies were misleading, as the studies failed to meet their primary endpoint of reducing clinical fracture rates, leading investors to purchase ADSs at inflated prices.
- Choosing Legal Counsel: The Rosen Law Firm advises investors to select qualified legal counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective representation in securities class actions.
- Investor Losses: The lawsuit claims that due to the defendants' misleading information, investors suffered damages, with the Rosen Law Firm having recovered over $438 million for investors in 2019, demonstrating its strong capabilities in securities class action litigation.
See More
Mereo BioPharma Faces Class Action Lawsuit
- Class Action Notification: The Portnoy Law Firm has advised Mereo BioPharma Group plc investors of a class action lawsuit for those who purchased securities between June 5, 2023, and December 26, 2025, with a deadline of April 6, 2026, to file a lead plaintiff motion to protect their legal rights.
- False Statements Exposed: The complaint alleges that Mereo misled investors by providing overwhelmingly positive statements while concealing significant adverse facts regarding the true status of its Phase 3 ORBIT and COSMIC trials, which misled investors about the company's actual condition and affected investment decisions.
- Clinical Trial Failures: On December 29, 2025, Mereo announced that neither the ORBIT nor the COSMIC Phase 3 studies achieved statistical significance, failing to meet their primary endpoint of reducing clinical fracture rates compared to placebo or bisphosphonates, despite improvements in bone mineral density.
- Stock Price Collapse: Following the negative announcement, Mereo's ADS price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, representing a decline of over 87.7%, severely impacting investors' asset values.
See More
Mereo BioPharma Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Mereo BioPharma Group plc for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 5, 2023, and December 26, 2025, with a deadline to contact the firm by April 6, 2026.
- False Statements Exposed: The complaint alleges that Mereo concealed negative facts regarding its Phase 3 ORBIT and COSMIC programs, resulting in the company's public statements being false and materially misleading throughout the class period, leading to investor losses when the truth emerged.
- Opportunity for Loss Recovery: Investors are encouraged to join the lawsuit to recover their losses, with the Schall Law Firm specializing in securities class actions and offering free consultations to help affected shareholders understand their rights.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, potentially affecting their ability to claim damages.
See More
Investors Alert: Deadline for Class Action Lawsuits Approaches
- Lawsuit Overview: Holzer & Holzer, LLC reminds investors of the class action lawsuit against BlackRock TCP Capital Corp., alleging that from November 6, 2024, to January 23, 2026, the company failed to appropriately value investments, resulting in significant investor losses.
- Mereo BioPharma Lawsuit: The class action against Mereo BioPharma Group plc claims that between June 5, 2023, and December 26, 2025, the company did not disclose material facts regarding setrusumab's statistical significance in the ORBIT and COSMIC studies, impacting investor confidence.
- Pomdoctor Lawsuit: The class action against Pomdoctor Limited alleges involvement in a fraudulent stock promotion scheme through social media misinformation from October 9, 2025, to December 11, 2025, leading to investor losses, with a deadline of April 6, 2026, to apply as lead plaintiff.
- Ultragenyx Lawsuit: The class action against Ultragenyx Pharmaceutical Inc. alleges failure to disclose expected results for its Phase III studies from August 3, 2023, to December 26, 2025, urging investors to act before the April 6, 2026, deadline.
See More
Class Action Filed Against Mereo BioPharma Group plc for Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Mereo BioPharma Group plc, alleging violations of federal securities laws on behalf of all investors who purchased Mereo securities between June 5, 2023, and December 26, 2025.
- False Statements Allegations: The complaint claims that throughout the class period, the defendants made overly positive statements while concealing significant adverse facts regarding the Phase 3 ORBIT and COSMIC programs, misleading investors about the company's true condition.
- Investor Actions: Affected investors are encouraged to apply to be lead plaintiffs by April 6, 2026, to share in any potential recovery, with the assurance that participation does not require serving as lead plaintiff.
- Law Firm's Strength: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors, emphasizing its commitment to restoring investor capital and ensuring corporate accountability.
See More
Mereo BioPharma Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Mereo BioPharma Group plc, encouraging those who purchased shares between June 5, 2023, and December 26, 2025, to contact the firm regarding potential lead plaintiff status for recovery.
- False Statements Allegations: The complaint alleges that Mereo provided overly positive statements about the Phase 3 ORBIT and COSMIC programs while concealing significant adverse facts, misleading investors about the trials' failure to meet primary endpoints.
- Stock Price Collapse: Following a press release on December 29, 2025, stating that neither study achieved statistical significance, Mereo's ADS price plummeted from $2.31 on December 26, 2025, to $0.29, representing a decline of over 87.7%.
- Claim Deadline: Shareholders must register by April 6, 2026, to participate in the class action lawsuit, and upon registration, they will receive updates on the case's progress to ensure their rights are protected.
See More
Class Action Notice for Mereo BioPharma Investors
- Class Action Deadline: Investors in Mereo BioPharma Group plc must note that the deadline to apply as lead plaintiff is April 6, 2026, covering the period from June 5, 2023, to December 26, 2025, and failure to apply may result in loss of claims.
- Lawsuit Background: The lawsuit alleges that Mereo's positive statements regarding setrusumab in its Phase 3 Orbit and COSMIC studies were misleading, as the studies failed to meet their primary endpoint of reducing clinical fracture rates, leading investors to purchase ADSs at inflated prices.
- Choosing Legal Counsel: The Rosen Law Firm advises investors to select qualified legal counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective representation in securities class actions.
- Investor Losses: The lawsuit claims that due to the defendants' misleading information, investors suffered damages, with the Rosen Law Firm having recovered over $438 million for investors in 2019, demonstrating its strong capabilities in securities class action litigation.
See More
Mereo BioPharma Faces Class Action Lawsuit
- Class Action Notification: The Portnoy Law Firm has advised Mereo BioPharma Group plc investors of a class action lawsuit for those who purchased securities between June 5, 2023, and December 26, 2025, with a deadline of April 6, 2026, to file a lead plaintiff motion to protect their legal rights.
- False Statements Exposed: The complaint alleges that Mereo misled investors by providing overwhelmingly positive statements while concealing significant adverse facts regarding the true status of its Phase 3 ORBIT and COSMIC trials, which misled investors about the company's actual condition and affected investment decisions.
- Clinical Trial Failures: On December 29, 2025, Mereo announced that neither the ORBIT nor the COSMIC Phase 3 studies achieved statistical significance, failing to meet their primary endpoint of reducing clinical fracture rates compared to placebo or bisphosphonates, despite improvements in bone mineral density.
- Stock Price Collapse: Following the negative announcement, Mereo's ADS price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, representing a decline of over 87.7%, severely impacting investors' asset values.
See More
Mereo BioPharma Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Mereo BioPharma Group plc for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 5, 2023, and December 26, 2025, with a deadline to contact the firm by April 6, 2026.
- False Statements Exposed: The complaint alleges that Mereo concealed negative facts regarding its Phase 3 ORBIT and COSMIC programs, resulting in the company's public statements being false and materially misleading throughout the class period, leading to investor losses when the truth emerged.
- Opportunity for Loss Recovery: Investors are encouraged to join the lawsuit to recover their losses, with the Schall Law Firm specializing in securities class actions and offering free consultations to help affected shareholders understand their rights.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, potentially affecting their ability to claim damages.
See More
